Genetic and clinical analysis of a novel GLB1 gene variant in a Chinese patient with GM1-gangliosidosis.
10.3760.cma.j.cn511374-20210415-00332
- Author:
Shuangxi CHENG
1
;
Qingming WANG
;
Aixin CHEN
;
Lingfang ZHOU
;
Xiaochun HONG
;
Haiming YUAN
Author Information
1. Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong 523120, China. haimingyuan@sina.cn.
- Publication Type:Journal Article
- MeSH:
Asians/genetics*;
China;
Female;
G(M1) Ganglioside;
Gangliosidosis, GM1/genetics*;
Humans;
Mutation;
beta-Galactosidase/genetics*
- From:
Chinese Journal of Medical Genetics
2022;39(5):537-541
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the genotype-phenotype correlation of a case with GM1-gangliosidosis caused by compound heterogenic variants in GLB1.
METHODS:Genomic DNA was extracted from peripheral blood samples from the patient and her parents. Trio-based whole-exome sequencing (WES) was performed for the family and suspected mutation was verified by Sanger sequencing.
RESULTS:The proband, a 2-year-3-month old Chinese girl, presented with psychomotor deterioration, absent speech, intellectual disabilities and behavior problem. Trio-based WES has identified compound heterozygosity for 2 variants in the GLB1 gene: NM_000404.2:c.1343A>T, p.Asp448Val and c.1064A>C, p.Gln355Pro (GRCh37/hg19),which was inherited from the mother and father, respectively. Homozygous or compound heterozygous pathogenic variants in GLB1, encoding β-galactosidase, are responsible for GM1-gangliosidosis,an autosomal recessive lysosomal storage disorder characterized by variable degrees of neurodegeneration and skeletal abnormalities. The p.Asp448Val variant has been classified as pathogenic for GM1 gangliosidosis in medical literatures for the reason that functional studies demonstrated that expression of the p.Asp448Val variant in COS-1 cells resulted in no detectable β-galactosidase activity compared to wild type GLB1. The p.Gln355Pro variant has not been reported in literatures or database. The variant is highly conserved residue (PM1), and was not found in either the Genome Aggregation Database or the 1000 Genomes Project (PM2) and was predicted to have a deleterious effect on the gene product by multiple in silico prediction tools (PP3). Next, the β-galactosidase activity of the patient's peripheral blood leukocytes was determined by fluorescent method. The result was 0.0 nmol/mg. It showed that the p.Gln355Pro variant also resulted in loss of β-galactosidase activity, thus the variant was classified into clinical pathogenic variant.
CONCLUSION:Our study expands the mutational spectrum of the GLB1 gene and provides genetic counseling for the family.
